Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Up 957.1% in July

Key Points

• Basilea Pharmaceutica AG experienced a significant increase in short interest, rising by 957.1% in July, totaling 7,400 shares as of July 15th.
• The stock's current trading price is $67.75, with a one year high of this amount, and a low of $47.50.
• Basilea focuses on developing products for oncology and anti-infectives and markets the antifungal drug Cresemba for severe infections.

Basilea Pharmaceutica AG (OTCMKTS:BPMUF - Get Free Report) saw a large growth in short interest during the month of July. As of July 15th, there was short interest totaling 7,400 shares, agrowthof957.1% from the June 30th total of 700 shares. Based on an average trading volume of 100 shares, the short-interest ratio is presently 74.0 days. Based on an average trading volume of 100 shares, the short-interest ratio is presently 74.0 days.

Basilea Pharmaceutica Stock Performance

Shares of BPMUF remained flat at $67.75 during trading hours on Wednesday. The company has a current ratio of 4.85, a quick ratio of 4.16 and a debt-to-equity ratio of 1.18. Basilea Pharmaceutica has a fifty-two week low of $47.50 and a fifty-two week high of $67.75. The business's 50 day moving average is $58.81 and its 200-day moving average is $54.00.

About Basilea Pharmaceutica

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.